A Model of Risk Analysis in Analytical Methodology for Biopharmaceutical Quality Control

Reference

1. 1.↵
   International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B. ICH Harmonised Tripartite Guideline: Geneva, Switzerland, 1999; pp 1–16.
2. 2.
   U.S. FDA Center for Biologics Evaluation and Research. Points To Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. U.S. Department of Health and Human Services: Washington, DC, 1997.
3. 3.↵
   1. Akyar I.

   1. Lotfipour F.,
   2. Hallaj-Nezhadi S.

   Microbial Quality Concerns for Biopharmaceuticals. In Latest Research into Quality Control, Akyar I., Ed.; InTech Open Access Publisher, 2012.
4. 4.↵
   1. Mehta S.,
   2. Keer J. T.

   Performance Characteristics of Host-Cell DNA Quantification Methods. BioProcess Int. 2007, 5 (9), 44.

   OpenUrl
5. 5.↵
   1. Wolter T.,
   2. Richter A.

   Assays for Controlling Host-Cell Impurities in Biopharmaceuticals. BioProcess Int. 2005, 3 (2), 40–46.

   OpenUrl
6. 6.↵
   World Health Organization. Technical Report Series, No. 814. Annex 3 Guidelines on the Quality, Safety, and Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA technology, 2013.
7. 7.↵
   U.S. FDA. Vaccines and Related Biological Products Advisory Committee Meeting, 2012, pp 1–30.
8. 8.↵
   World Health Organization. Meeting Report—WHO Study Group on Cell Substrates for Production of Biologicals, WHO Headquarters, Geneva, June 2007, pp 11–12.
9. 9.↵
   USP. USP37-NF32. United States Pharmacopeial Convention: Rockville, MD, 2013.
10. 10.↵
    International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Quality Risk Management Q9. ICH Harmonised Tripartite Guideline: Geneva, Switzerland, November 2005, pp 1–19.
11. 11.↵
    1. Griffith E.

    Risk Management Programs for the Pharmaceutical Industry. Fujitsu Consulting, white paper, pharmaceutical industry 2004, retrieved from http://www.fujitsu.com/downloads/SVC/fc/wp/pharma-risk-mgmt.pdf (Accessed February 6, 2012).
12. 12.↵
    1. Pérez J. R.

    Quality Risk Management in the FDA-Regulated Industry; ASQ Quality Press: Milwaukee, WI, 2012.
13. 13.↵
    1. Mortimore S.,
    2. Wallace C.

    HACCP: A Practical Approach, 3rd ed.; Springer Science & Business Media: Berlin, Germany, 2012.
14. 14.↵
    1. Banaitiene N.

    1. Botet J.

    Quality Risk Analysis: Value for Money in the Pharmaceutical Industry. In Risk Management—Current Issues and Challenges, Banaitiene N., Ed.; InTech: Rijeka, Croatia, 2012; pp 387–410.
15. 15.↵
    1. Sjöberg A.-M.,
    2. Sillanpää J.,
    3. Sipiläinen-Malm T.,
    4. Weber A.,
    5. Raaska L.

    An Implementation of the HACCP System in the Production of Food-Packaging Material. J Ind Microbiol Biot, 2002, 28 (4), 213–218.

    OpenUrlPubMed
16. 16.↵
    1. Trafiałek J.,
    2. Lehrke M.,
    3. Lücke F. K.,
    4. Kołożyn-Krajewska D.,
    5. Janssen J.

    HACCP-Based Procedures in Germany and Poland. Food Control 2015, 55, 66–74.

    OpenUrl
17. 17.↵
    World Health Organization. Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials, 2nd ed.; World Health Organization: Geneva, Switzerland, 2007; Vol 2.
18. 18.↵
    World Health Organization. Hazard Analysis and Critical Control Point Generic Models for Some Traditional Foods: A Manual for the Eastern Mediterranean Region; World Health Organization: Geneva, Switzerland, 2010.
19. 19.↵
    1. Peraman R.,
    2. Bhadraya K.,
    3. Reddy Y. P.

    Analytical Quality by Design: A Tool for Regulatory Flexibility and Robust Analytics. Int. J. Anal. Chem. 2015, 1–9.
20. 20.↵
    1. Boulanger B.,
    2. Dewé W.,
    3. Gilbert A.,
    4. Govaerts B.,
    5. Maumy-Bertrand M.

    Risk Management for Analytical Methods Based on the Total Error Concept: Conciliating the Objectives of the Pre-Study and In-Study Validation Phases. Chemom. Intell. Lab. Syst. 2007, 86 (2), 198–207.

    OpenUrl
21. 21.↵
    1. Santos-Reyes J.,
    2. Beard A. N.

    Assessing Safety Management Systems. J. Loss Prevent. Proc. Ind. 2002, 15 (2), 77–95.

    OpenUrl
22. 22.↵
    International Organization for Standardization /International Electrotechnical Commission (ISO/IEC). ISO/IEC Guide 51, Safety Aspects—Guidelines for Their Inclusion in Standards, 2nd ed.; ISO/IEC: Geneva, Switzerland, 1999.
23. 23.↵
    1. Korczynski M. S.

    The Integration of Process Analytical Technologies, Concurrent Validation, and Parametric Release Programs in Aseptic Processing. PDA J. Pharm. Sci. Technol. 2004, 58 (4), 181–191.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Katayama H.,
    2. Higo T.,
    3. Tokunaga Y.,
    4. Hiyama Y.,
    5. Morikawa K.

    Establishment of Critical Contamination Risk Locations (“Hot Spots”) in Environmental Monitoring by Means of Three-Dimensional Airflow Analysis and Particulate Evaluation. PDA J. Pharm. Sci. Technol. 2005, 59 (1), 49–63.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Sandle T.

    Application of Quality Risk Management To Set Viable Environmental Monitoring Frequencies in Biotechnology Processing and Support Areas. PDA J. Pharm. Sci. Technol. 2012, 66 (6), 560–579.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Eansoë-Bourget E.

    Risk Assessment Paradigm: An Opportunity for Rationalizing the Choice of Biological Indicator during the Validation of Isolator Biodecontamination Cycles. PDA J. Pharm. Sci. Technol. 2006, 60 (3), 156–163.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Angel de la O Herrera M.,
    2. Luna A. S.,
    3. da Costa A. C. A.,
    4. Blanco Lemes E. M.

    A Structural Approach to the HAZOP—Hazard and Operability Technique in the Biopharmaceutical Industry. J. Loss Prevent. Proc. Ind. 2015, 35, 1–11.

    OpenUrl
28. 28.↵
    1. Baybutt P.

    Requirements for Improved Process Hazard Analysis (PHA) Methods. J. Loss Prevent. Proc. Ind. 2014, 32, 182–191.

    OpenUrl
29. 29.↵
    1. Sperber W. H.,
    2. Stier R. F.

    Happy 50^th Birthday to HACCP: Retrospective and Prospective. Food Safety Magazine 2009, 42, 44–46.

    OpenUrl
30. 30.↵
    World Health Organization. Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) Methodology to Pharmaceuticals; World Health Organization: Geneva, Switzerland, 2003; pp 99–112.
31. 31.↵
    U.S. FDA. HACCP Principles & Application Guidelines. Retrieved from http://www.fda.gov/Food/GuidanceRegulation/HACCP/ucm2006801.htm#app-f, 1997 (Accessed MarCH 6, 2015).
32. 32.↵
    1. Havelaar A. H.

    Application of HACCP to Drinking Water Supply. Food Control 1994, 5 (3), 145–152.

    OpenUrlCrossRef
33. 33.↵
    1. Bonan B.,
    2. Martelli N.,
    3. Berhoune M.,
    4. Maestroni M.-L.,
    5. Havard L.,
    6. Prognon P.

    The Application of Hazard Analysis and Critical Control Points and Risk Management in the Preparation of Anti-Cancer Drugs. Int. J. Quality Health Care 2009, 21 (1), 44–50.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Jahnke M.,
    2. Kühn K.-D.

    Use of the Hazard Analysis and Critical Control Points (HACCP) Risk Assessment on a Medical Device for Parenteral Application. PDA J. Pharm. Sci. Technol, 2003, 57 (1), 32–42.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Kessels-Habraken M.,
    2. Van Der Schaaf T.,
    3. De Jonge J.,
    4. Rutte C.,
    5. Kerkvliet K.

    Integration of Prospective and Retrospective Methods for Risk Analysis in Hospitals. Int. J. Quality Health Care 2009, 21 (6), 427–432.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Chatterjee M. B.

    Applying Lean Six Sigma in the Pharmaceutical Industry; Ashgate Publishing, Ltd.: Farnham, UK, 2014.
37. 37.↵
    1. Tague N. R.

    The Quality Toolbox, 2nd ed.; ASQ Quality Press Milwaukee, WI, 2010.
38. 38.↵
    1. McDermott R. E.,
    2. Mikulak R. J.,
    3. Beauregard M. R.

    The Basics of FMEA, 2nd ed.; CRC Press: New York, 2008.
39. 39.↵
    International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Pharmaceutical Development Q8. ICH Harmonised Tripartite Guideline: Geneva, Switzerland, August 2009; pp 1–28.